S. Philipp

发表

S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update

H. Orzechowski, K. Reich, M. Sebastian, 2012, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

German S3-guidelines on the treatment of psoriasis vulgaris (short version)

H. Orzechowski, K. Reich, B. Rzany, 2012, Archives of Dermatological Research.

S3 – Guidelines on the treatment of psoriasis vulgaris Update 2011

H. Orzechowski, K. Reich, M. Sebastian, 2011 .

Etanercept: overview of clinical experience in the treatment of psoriasis and psoriatic arthritis

G. Kokolakis, W. Sterry, S. Philipp, 2011 .

The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder

H. Volk, W. Sterry, R. Sabat, 2006, Expert opinion on therapeutic targets.

Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO‐INSIGHTFUL study

K. Papp, K. Papp, S. Philipp, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label CADMUS Jr study

A. Paller, M. Song, L. Eichenfield, 2020, The British journal of dermatology.

Sustained long‐term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double‐blind, phase III study

K. Papp, M. Seyger, K. Unnebrink, 2019, The British journal of dermatology.

S2k guidelines for the treatment of psoriasis in children and adolescents – Short version part 1

M. Sticherling, M. Augustin, T. Weberschock, 2019, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Psoriasis in different life situations

S. Philipp, 2014 .

Effects of tissue-tolerable plasma on psoriasis vulgaris treatment compared to conventional local treatment: A pilot study

A. Kramer, J. Lademann, W. Sterry, 2014 .

Poly(ADP-Ribose) Polymerase Mediates Inflammation in a Mouse Model of Contact Hypersensitivity

Dean P. Jones, S. Wolffram, H. Merkle, 2009 .

Safety and efficacy of the tumor necrosis factor antagonists.

W. Sterry, A. Nast, S. Philipp, 2010, Seminars in cutaneous medicine and surgery.

Recommendations for detection of individual risk for comorbidities in patients with psoriasis

W. Koenig, A. Pfeiffer, J. Wohlrab, 2013, Archives of Dermatological Research.

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis

M. Gooderham, K. Papp, A. Blauvelt, 2020, JAMA dermatology.

Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker – a retrospective multicenter study

S. Philipp, R. Mössner, S. Gerdes, 2020, The Journal of dermatological treatment.

Drug survival and reasons for drug discontinuation in palmoplantar pustulosis: a retrospective multicenter study

W. Peitsch, M. Dakna, A. Schmieder, 2019, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in Psoriasis.

K. Asadullah, H. Volk, W. Sterry, 2002, The Journal of investigative dermatology.

Application of Photoacoustic Methods and Confocal Microscopy for Monitoring of Therapeutic Response in Plaque Psoriasis

J. Lademann, H. Richter, S. Philipp, 2018, Skin Pharmacology and Physiology.

Therapeutic potential of selectin antagonists in psoriasis

G. Wolff, S. Philipp, D. Bock, 2006, Expert opinion on investigational drugs.

Risankizumab versus Ustekinumab for Moderate‐to‐Severe Plaque Psoriasis

A. Menter, M. Gooderham, K. Papp, 2017, The New England journal of medicine.

Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study.

A. Paller, A. Menter, L. Eichenfield, 2015, Journal of the American Academy of Dermatology.

The genetic basis for most patients with pustular skin disease remains elusive

K. Schäkel, S. Kõks, H. Sticht, 2018, The British journal of dermatology.

German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 2: Treatment monitoring and specific clinical or comorbid situations

K. Reich, M. Sebastian, M. Augustin, 2021, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Genetic analysis of MPO variants in four psoriasis subtypes in patients from Germany.

K. Schäkel, G. Schett, A. Reis, 2021, The Journal of investigative dermatology.

Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial

K. Papp, K. Unnebrink, D. Thaçi, 2017, The Lancet.

S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 1 – Systemic treatment

K. Reich, M. Sebastian, M. Augustin, 2018, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 1: Treatment goals and treatment recommendations

K. Reich, M. Sebastian, M. Augustin, 2021, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

A. Gottlieb, E. Martı́n-Mola, A. Deodhar, 2018, The Lancet.

Palmoplantar pustulosis - a cross-sectional analysis in Germany.

Y. Frambach, S. Philipp, R. Mössner, 2017, Dermatology online journal.

Fluorescence optical imaging for the detection of potential psoriatic arthritis in comparison to musculoskeletal ultrasound

T. Zuberbier, G. Burmester, G. Kokolakis, 2019, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Successful treatment of delayed pressure urticaria with anti-TNF-alpha.

M. Maurer, S. Philipp, M. Friedrich, 2007, The Journal of allergy and clinical immunology.

Expression of Tolerance Associated Gene-1, a Mitochondrial Protein Inhibiting T Cell Activation, Can Be Used to Predict Response to Immune Modulating Therapies1

C. Meisel, H. Volk, W. Sterry, 2009, The Journal of Immunology.

Three decades of psoriasis research: where has it led us?

W. Sterry, R. Sabat, S. Philipp, 2007, Clinics in dermatology.

B. Strober, N. Zhang, A. Costanzo, 2017, Journal of the American Academy of Dermatology.

A comprehensive, tri‐national, cross‐sectional analysis of characteristics and impact of pruritus in psoriasis

G. Kokolakis, R. Sabat, M. Maurer, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

Safety of Systemic Agents for the Treatment of Pediatric Psoriasis

D. West, K. Holland, J. Lambert, 2017, JAMA dermatology.

Systemic Antipsoriatic Combination Therapy with Fumaric Acid Esters for Plaque-Type Psoriasis: Report on 17 Cases

Y. Frambach, S. Philipp, R. Mössner, 2015, Dermatology.

Nausea and vomiting in fractionated radiotherapy: a prospective on-demand trial of tropisetron rescue for non-responders to metoclopramide.

A. Rosset, P. Coucke, R. Miralbell, 1995, European journal of cancer.

Relationship between Histological and Clinical Course of Psoriasis: A Pilot Investigation by Reflectance Confocal Microscopy during Goeckerman Treatment

H. Duerr, M. Ulrich, M. Meinke, 2016, Skin Pharmacology and Physiology.

Treatment of plaque psoriasis

K. Kragballe, S. Philipp, P. Kerkhof, 2014 .

S1 guidelines on the diagnosis and treatment of scabies – short version

J. Stingl, A. Nast, S. Philipp, 2016, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Increased Prevalence of Metabolic Syndrome in Patients with Acne Inversa

G. Kokolakis, S. Schneider-Burrus, W. Sterry, 2012, PloS one.

Secukinumab improves hand, foot and nail lesions in moderate‐to‐severe plaque psoriasis: subanalysis of a randomized, double‐blind, placebo‐controlled, regimen‐finding phase 2 trial

A. Gottlieb, K. Reich, U. Mrowietz, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Scabies outbreak among healthcare workers in a German acute care hospital

S. Philipp, R. Leistner, D. Buchwald, 2017, Journal of infection prevention.

Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: Experience from a consecutive cohort of inflammatory bowel disease patients

U. Grittner, D. Baumgart, S. Philipp, 2011, Inflammatory bowel diseases.

Prevalence and factors associated with sleep disturbance in adult patients with psoriasis

G. Kokolakis, R. Sabat, S. Philipp, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

Combination of adalimumab with traditional systemic antipsoriatic drugs – a report of 39 cases

Y. Frambach, S. Philipp, R. Mössner, 2012, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-γ are not

H. Volk, Wenfeng Xu, H. Haugen, 2009, Journal of Molecular Medicine.

Immunopathogenesis of psoriasis

Khusru Asadullah, Wolfram Sterry, K. Asadullah, 2007, Experimental dermatology.

Myeloperoxidase Modulates Inflammation in Generalized Pustular Psoriasis and Additional Rare Pustular Skin Diseases

W. Sondermann, K. Schäkel, A. Ekici, 2020, American journal of human genetics.

Palmoplantar Pustular Psoriasis Is Associated with Missense Variants in CARD14, but Not with Loss-of-Function Mutations in IL36RN in European Patients.

S. Kõks, H. Sticht, M. Sticherling, 2015, The Journal of investigative dermatology.

Neuroimmunological links in dermatology: psoriasis as a model disease in stress research

W. Sterry, R. Sabat, S. Philipp, 2012 .

Biologics for atopic diseases: Indication, side effect management, and new developments

T. Zuberbier, K. Bergmann, L. Klimek, 2021, Allergologie select.

S2k guidelines for the treatment of psoriasis in children and adolescents – Short version part 2

M. Sticherling, M. Augustin, T. Weberschock, 2019, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Efficacy and safety of fumaric acid esters in patients with psoriasis on medication for comorbid conditions – a retrospective evaluation (FACTS)

K. Reich, M. Augustin, D. Thaçi, 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Psoriasis therapy in children

S. Philipp, 2014 .

Confocal laser-scanning microscopy of capillaries in normal and psoriatic skin

Wolfram Sterry, Alexa Patzelt, Juergen Lademann, 2012, Journal of biomedical optics.

Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent

K. Pavelka, L. Puig, F. V. D. van den Hoogen, 2018, BioDrugs.

The Th17 cytokine IL‐22 induces IL‐20 production in keratinocytes: A novel immunological cascade with potential relevance in psoriasis

K. Asadullah, G. Schulze-Tanzil, H. Volk, 2009, European journal of immunology.

B. Strober, A. Costanzo, N. Zhang, 2017, The British journal of dermatology.

Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three‐year results from the UNCOVER‐3 study

S. Ball, L. Puig, C. Leonardi, 2018, Journal of the American Academy of Dermatology.

Efficacy of Adalimumab for Nail Psoriasis During 24 Months of Continuous Therapy

G. Kokolakis, R. Sabat, S. Philipp, 2020, Acta dermato-venereologica.

IL-19 is a component of the pathogenetic IL-23/IL-17 cascade in psoriasis.

K. Asadullah, H. Volk, N. Babel, 2014, The Journal of investigative dermatology.

Characterisation of hand small joints arthropathy using high-resolution MRI—Limited discrimination between osteoarthritis and psoriatic arthritis

B. Hamm, A. Tan, S. Philipp, 2013, European Radiology.

IL-29 Is Produced by TH17 Cells and Mediates the Cutaneous Antiviral Competence in Psoriasis

M. Raftery, H. Volk, G. Schönrich, 2013, Science Translational Medicine.

Skin Sodium Accumulates in Psoriasis and Reflects Disease Severity.

M. Kelm, A. Waisman, T. Kuehne, 2021, The Journal of investigative dermatology.

Evidence‐based (S3) guideline for the treatment of psoriasis vulgaris – Update: “Therapeutic options” and “Efalizumab”

K. Reich, M. Sebastian, M. Augustin, 2010 .

Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab".

K. Reich, M. Sebastian, M. Augustin, 2010, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent

K. Pavelka, L. Puig, F. V. D. van den Hoogen, 2018, BioDrugs.

S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 2 – Special patient populations and treatment situations

K. Reich, M. Sebastian, M. Augustin, 2018, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Pan-selectin antagonism improves psoriasis manifestation in mice and man

Sewon Kang, G. Wolff, W. Sterry, 2006, Archives of Dermatological Research.

Immunological changes in psoriasis patients under long-term treatment with fumaric acid esters: risk of Kaposi sarcoma occurrence?

G. Kokolakis, W. Sterry, R. Sabat, 2013, European journal of dermatology : EJD.

Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.

A. Gottlieb, A. Blauvelt, B. Sigurgeirsson, 2015, Journal of drugs in dermatology : JDD.

Colophony‐induced contact dermatitis due to ECG electrodes in an infant

T. Zuberbier, M. Worm, S. Philipp, 2007, Contact dermatitis.

[Preclinical safety evaluation of chloral hydrate after topical application using the example of psoriatic itch].

J. Wohlrab, S. Philipp, M. Fischer, 2016, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

Wolk Competence in Psoriasis 17 Cells and Mediates the Cutaneous AntiviralHIL-29 Is Produced by T

M. Raftery, H. Volk, G. Schönrich, 2013 .

Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: Experience from a consecutive cohort of inflammatory bowel disease patients

U. Grittner, D. Baumgart, S. Philipp, 2011, Inflammatory Bowel Diseases.

Expression of Tolerance Associated Gene-1, a Mitochondrial Protein Inhibiting T Cell Activation, Can Be Used to Predict Response to Immune Modulating Therapies1

Sandra, C. Meisel, H. Volk, 2009, The Journal of Immunology.

S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 1 – Systemic treatment

K. Reich, M. Sebastian, M. Augustin, 2018, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Neue Erkenntnisse zu Fumarsäureestern (Fumaderm®): Ergebnisse eines Experten‐Workshops

B. Bonnekoh, T. Gambichler, T. Luger, 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Relationship between Histological and Clinical Course of Psoriasis: A Pilot Investigation by Reflectance Confocal Microscopy during Goeckerman Treatment

H. Duerr, M. Ulrich, M. Meinke, 2016, Skin Pharmacology and Physiology.

Therapeutic aim of psoriasis therapy

S. Philipp, 2014 .